Complement driven by conformational changes

Nature Reviews Immunology

Volumn 8, Issue 1, 2008, Pages 48-58

  Gros, Piet ^a   Milder, Fin J ^a   Janssen, Bert J C ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; PROTEINASE ACTIVATED RECEPTOR 1;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CYTOLYSIS; HOST RESISTANCE; LYMPHOCYTE ACTIVATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT FACTOR B; HUMANS;

EID: 37549023083     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2231     Document Type: Review

References (86)

1. Walport, M. J. Complement. First of two parts. N. Engl. J. Med. 344, 1058-1066 (2001).
2. Nonaka, M. & Kimura, A. Genomic view of the evolution of the complement system. Immunogenetics 58, 701-713 (2006).
3. Kirkitadze, M. D. & Barlow, P. N. Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol. Rev. 180, 146-161 (2001).
4. Sahu, A. & Lambris, J. D. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 49, 133-148 (2000).
5. Muller-Eberhard, H. J. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57, 321-347 (1988).
6. Turner, M. W. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol. Today 17, 532-540 (1996).
7. Walport, M. J. Complement. Second of two parts. N. Engl. J. Med. 344, 1140-1144 (2001).
8. Endo, Y., Takahashi, M. & Fujita, T. Lectin complement system and pattern recognition. Immunobiology 211, 283-293 (2006).
9. Lambris, J. D. The multifunctional role of C3, the third component of complement. Immunol. Today 9, 387-393 (1988).
10. Sahu, A. & Lambris, J. D. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 180, 35-48 (2001).
11. Janssen, B. J. et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437, 505-511 (2005). This paper describes for the first time the structure of C3, which shows the arrangement of its 13 domains and the protected surroundings of the intact thioester moiety.
12. Fredslund, F. et al. The structure of bovine complement component 3 reveals the basis for thioester function. J. Mol. Biol. 361, 115-127 (2006).
13. Janssen, B. J., Christodoulidou, A., McCarthy, A., Lambris, J. D. & Gros, P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 444, 213-216 (2006).
14. Wiesmann, C. et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444, 217-220 (2006). References 13 and 14 reveal the large structural rearrangements that occur on activation of C3 into C3b. In addition, reference 14 reveals the binding of the macrophage receptor CRIg, which also inhibits C3 convertase activity.
15. Nishida, N., Walz, T. & Springer, T. A. Structural transitions of complement component C3 and its activation products. Proc. Natl Acad. Sci. USA 103, 19737-19742 (2006). By presenting electron-microscopy images, this paper provides a comprehensive view of the conformational states of C3 that underly its various activities.
16. Milder, F. J. et al. Factor B structure provides insights into activation of the central protease of the complement system. Nature Struct. Mol. Biol. 14, 224-228 (2007). This paper describes the full-length structure of the pro-enzyme factor B; the structure indicates that activation of factor B involves intricate conformational changes.
17. Ponnuraj, K. et al. Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. Mol. Cell 14, 17-28 (2004). This paper describes the two-domain structure of Bb and indicates that ligand binding to the A-domain is not sufficient to activate the catalytic machinery.
18. Milder, F. J. et al. Structure of complement component C2a: implications for convertase formation and substrate binding. Structure 14, 1587-1597 (2006).
19. Krishnan, V., Xu, Y., Macon, K., Volanakis, J. E. & Narayana, S. V. The crystal structure of C2a, the catalytic fragment of classical pathway C3 and C5 convertase of human complement. J. Mol. Biol. 367, 224-233 (2007). References 18 and 19 show that the primary ligand-binding domain of C2a is regulated differently from homologous I domains in integrins.
20. Blandin, S. & Levashina, E. A. Thioester-containing proteins and insect immunity. Mol. Immunol. 40, 903-908 (2004).
21. Budd, A., Blandin, S., Levashina, E. A. & Gibson, T. J. Bacterial α2-macroglobulins: colonization factors acquired by horizontal gene transfer from the metazoan genome? Genome Biol. 5, R38 (2004).
22. Alsenz, J., Becherer, J. D., Nilsson, B. & Lambris, J. D. Structural and functional analysis of C3 using monoclonal antibodies. Curr. Top. Microbiol Immunol. 153, 235-248 (1990).
23. Huber, R., Scholze, H., Paques, E. P. & Deisenhofer, J. Crystal structure analysis and molecular model of human C3a anaphylatoxin. Hoppe Seylers Z. Physiol. Chem. 361, 1389-1399 (1980).
24. Nagar, B., Jones, R. G., Diefenbach, R. J., Isenman, D. E. & Rini, J. M. X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 280, 1277-1281 (1998). This paper describes the structure of C3d, which reveals the activated, open state of the thioester moiety.
25. Abdul Ajees, A. et al. The structure of complement C3b provides insights into complement activation and regulation. Nature 444, 221-225 (2006).
26. Janssen, B. J., Read, R. J., Brunger, A. T. & Gros, P. Crystallography: crystallographic evidence for deviating C3b structure. Nature 448, E1-E2 (2007).
27. de Bruijn, M. H. & Fey, G. H. Human complement component C3: cDNA coding sequence and derived primary structure. Proc. Natl Acad. Sci. USA 82, 708-712 (1985).
28. Baxter, R. H. et al. Structural basis for conserved complement factor-like function in the antimalarial protein TEP1. Proc. Natl Acad. Sci. USA 104, 11615-11620 (2007).
29. Tack, B. F., Harrison, R. A., Janatova, J., Thomas, M. L. & Prahl, J. W. Evidence for presence of an internal thiolester bond in third component of human complement. Proc. Natl Acad. Sci. USA 77, 5764-5768 (1980).
30. Thomas, M. L., Janatova, J., Gray, W. R. & Tack, B. F. Third component of human complement: localization of the internal thiolester bond. Proc. Natl Acad. Sci. USA 79, 1054-1058 (1982).
31. Law, S. K. & Dodds, A. W. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci. 6, 263-274 (1997).
32. Pangburn, M. K., Schreiber, R. D. & Muller-Eberhard, H. J. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med. 154, 856-867 (1981).
33. Isenman, D. E., Kells, D. I., Cooper, N. R., Muller-Eberhard, H. J. & Pangburn, M. K. Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry 20, 4458-4467 (1981).
34. Pangburn, M. K. Spontaneous reformation of the intramolecular thioester in complement protein C3 and low temperature capture of a conformational intermediate capable of reformation. J. Biol. Chem. 267, 8584-8590 (1992).
35. Sim, R. B., Twose, T. M., Paterson, D. S. & Sim, E. The covalent-binding reaction of complement component C3. Biochem. J. 193, 115-127 (1981).
36. Taniguchi-Sidle, A. & Isenman, D. E. Interactions of human complement component C3 with factor B and with complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) involve an acidic sequence at the N-terminus of C3 α′-chain. J. Immunol. 153, 5285-5302 (1994).
37. Kolln, J., Spillner, E., Andra, J., Klensang, K. & Bredehorst, R. Complement inactivation by recombinant human C3 derivatives. J. Immunol. 173, 5540-5545 (2004).
38. Kolln, J., Bredehorst, R. & Spillner, E. Engineering of human complement component C3 for catalytic inhibition of complement. Immunol. Lett. 98, 49-56 (2005).
39. Daoudaki, M. E., Becherer, J. D. & Lambris, J. D. A 34-amino acid peptide of the third component of complement mediates properdin binding. J. Immunol. 140, 1577-1580 (1988).
40. Hourcade, D. E. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J. Biol. Chem. 281, 2128-2132 (2006).
41. Fishelson, Z. Complement C3: a molecular mosaic of binding sites. Mol. Immunol. 28, 545-552 (1991).
42. Becherer, J. D., Alsenz, J., Esparza, I., Hack, C. E. & Lambris, J. D. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B. Biochemistry 31, 1787-1794 (1992).
43. Lambris, J. D. et al. Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component. J. Immunol. 156, 4821-4832 (1996).
44. Oran, A. E. & Isenman, D. E. Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35). J. Biol. Chem. 274, 5120-5130 (1999).
45. Lambris, J. D., Avila, D., Becherer, J. D. & Muller-Eberhard, H. J. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides. J. Biol. Chem. 263, 12147-12150 (1988).
46. Pangburn, M. K. & Rawal, N. Structure and function of complement C5 convertase enzymes. Biochem. Soc. Trans. 30, 1006-1010 (2002).
47. Muller-Eberhard, H. J. The membrane attack complex of complement. Annu. Rev. Immunol. 4, 503-528 (1986).
48. Carroll, M. C. The complement system in regulation of adaptive immunity. Nature Immunol. 5, 981-986 (2004).
49. Helmy, K. Y. et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124, 915-927 (2006).
50. Gilbert, H. E., Eaton, J. T., Hannan, J. P., Holers, V. M. & Perkins, S. J. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study. J. Mol. Biol. 346, 859-873 (2005).
51. Hannan, J. P. et al. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d. J. Mol. Biol. 346, 845-858 (2005).
52. Fishelson, Z., Pangburn, M. K. & Muller-Eberhard, H. J. Characterization of the initial C3 convertase of the alternative pathway of human complement. J. Immunol. 132, 1430-1434 (1984).
53. Kerr, M. A. The human complement system: assembly of the classical pathway C3 convertase. Biochem. J. 189, 173-181 (1980).
54. Fishelson, Z. & Muller-Eberhard, H. J. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b, Bb. J. Immunol. 132, 1425-1429 (1984).
55. 1. Cell 101, 47-56 (2000).
56. Shimaoka, M. et al. Structures of the αL I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112, 99-111 (2003).
57. Shimaoka, M. et al. Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin αL I domains with high affinity and antagonist activity in vivo. Proc. Natl Acad. Sci. USA 98, 6009-6014 (2001).
58. 1. J. Biol. Chem. 272, 28512-28517 (1997).
59. Horiuchi, T., Macon, K. J., Engler, J. A. & Volanakis, J. E. Site-directed mutagenesis of the region around Cys-241 of complement component C2. Evidence for a C4b binding site. J. Immunol. 147, 584-589 (1991).
60. Fishelson, Z., Pangburn, M. K. & Muller-Eberhard, H. J. C3 convertase of the alternative complement pathway. Demonstration of an active, stable C3b, Bb (Ni) complex. J. Biol. Chem. 258, 7411-7415 (1983).
61. Xu, Y. & Volanakis, J. E. Contribution of the complement control protein modules of C2 in C4b binding assessed by analysis of C2/factor B chimeras. J. Immunol. 158, 5958-5965 (1997).
62. Hourcade, D. E., Wagner, L. M. & Oglesby, T. J. Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis. J. Biol. Chem. 270, 19716-19722 (1995).
63. Pryzdial, E. L. & Isenman, D. E. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact. J. Biol. Chem. 262, 1519-1525 (1987).
64. Pryzdial, E. L. & Isenman, D. E. A reexamination of the role of magnesium in the human alternative pathway of complement. Mol. Immunol. 23, 87-96 (1986).
65. Khan, A. R. & James, M. N. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 7, 815-836 (1998).
66. Jing, H. et al. New structural motifs on the chymotrypsin fold and their potential roles in complement factor B. EMBO J. 19, 164-173 (2000).
67. Volanakis, J. E. & Narayana, S. V. Complement factor D, a novel serine protease. Protein Sci. 5, 553-564 (1996).
68. Jing, H. et al. Structures of native and complexed complement factor D: implications of the atypical His57 conformation and self-inhibitory loop in the regulation of specific serine protease activity. J. Mol. Biol. 282, 1061-1081 (1998).
69. Crump, M. P. et al. Structure of an allosteric inhibitor of LFA-1 bound to the I-domain studied by crystallography, NMR, and calorimetry. Biochemistry 43, 2394-2404 (2004).
70. Kallen, J. et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. 292, 1-9 (1999).
71. Wattanasin, S. et al. 1,4-Diazepane-2,5-diones as novel inhibitors of LFA-1. Bioorg Med. Chem. Lett. 15, 1217-1220 (2005).
72. Jenkins, H. T. et al. Human C4b-binding protein, structural basis for interaction with streptococcal M protein, a major bacterial virulence factor. J. Biol. Chem. 281, 3690-3697 (2006).
73. Stoiber, H., Kacani, L., Speth, C., Wurzner, R. & Dierich, M. P. The supportive role of complement in HIV pathogenesis. Immunol. Rev. 180, 168-176 (2001).
74. Brook, E., Herbert, A. P., Jenkins, H. T., Soares, D. C. & Barlow, P. N. Opportunities for new therapies based on the natural regulators of complement activation. Ann. NY Acad. Sci. 1056, 176-188 (2005).
75. Rooijakkers, S. H. & van Strijp, J. A. Bacterial complement evasion. Mol. Immunol. 44, 23-32 (2007).
76. Favoreel, H. W., Van de Walle, G. R., Nauwynck, H. J. & Pensaert, M. B. Virus complement evasion strategies. J. Gen. Virol. 84, 1-15 (2003).
77. Kotwal, G. J. & Moss, B. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335, 176-178 (1988).
78. McKenzie, R., Kotwal, G. J., Moss, B., Hammer, C. H. & Frank, M. M. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166, 1245-1250 (1992).
79. Kraiczy, P., Skerka, C., Kirschfink, M., Zipfel, P. F. & Brade, V. Mechanism of complement resistance of pathogenic Borrelia burgdorferi isolates. Int. Immunopharmacol. 1, 393-401 (2001).
80. Hammel, M. et al. A structural basis for complement inhibition by Staphylococcus aureus. Nature Immunol. 8, 430-437 (2007).
81. Rooijakkers, S. H. et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nature Immunol. 6, 920-927 (2005).
82. Sim, R. B. & Tsiftsoglou, S. A. Proteases of the complement system. Biochem. Soc. Trans. 32, 21-27 (2004).
83. Kuhlman, M., Joiner, K. & Ezekowitz, R. A. The human mannose-binding protein functions as an opsonin. J. Exp. Med. 169, 1733-1745 (1989).
84. Matsushita, M. & Fujita, T. Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation. Immunobiology 194, 443-448 (1995).
85. Thiel, S. et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 386, 506-510 (1997).
86. Pangburn, M. K. & Muller-Eberhard, H. J. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J. Exp. Med. 152, 1102-1114 (1980).